www.ScienceTranslationalMedicine.org 12 January 2011 Vol 3 Issue 65 65ra4

Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation Sequencing

Callum J. Bell,¹* Darrell L. Dinwiddie,^{1,2}* Neil A. Miller,^{1,2} Shannon L. Hateley,¹ Elena E. Ganusova,¹ Joann Mudge,¹ Ray J. Langley,¹ Lu Zhang,³ Clarence C. Lee,⁴ Faye D. Schilkey,¹ Vrunda Sheth,⁴ Jimmy E. Woodward,¹ Heather E. Peckham,⁴ Gary P. Schroth,³ Ryan W. Kim,¹ Stephen F. Kingsmore^{1,2†}

¹National Center for Genome Resources, Santa Fe, NM 87505, USA. ²Children's Mercy Hospital, Kansas City, MO 64108, USA. ³Illumina Inc., Hayward, CA 94545, USA. ⁴Life Technologies, Beverley, MA 01915, USA. *These authors contributed equally to this work. †To whom correspondence should be addressed. E-mail: sfk@ncgr.org

> Presented by: Baikang Pei Journal Club, Gerstein Lab, 2011-01-25

Tay-Sachs Disease (TSD)

TSD: an autosomal recessive neurodegnerative disorder

Onset of symptoms in infancy and death by 2 to 5 years of age

Premature death of nerve cells of the brain due to gangliosides accumulation

TSD is incurable, but treatments are available

Affected couples may decide not to have children or to conceive a child using IVF treatment







Preconception Screening



Of 7028 disorders with suspected Mendelian inheritance, 1139 are recessive and have an established molecular basis.

They account for ~20% of infant mortality and ~10% of pediatric hospitalizations.

To date, preconception carrier testing has been recommended in the USA only for five diseases.

Some major obstacles

Rear disease, high cost, absence of accurate, sensitive and scalable technologies

Target Capture and NGS

Target capture and NGS are considered as a potential paradigm for carrier testing for their cost-effectiveness and broad coverage of mutations.

Target capture: to targeted and amplified particular sequences in DNA samples that were known to be associated with the recessive disease genes

Challenges

More stringent sensitivity and specificity are required for routine use in clinical practice than usual genome research

Design

Disease Inclusion

448 diseases were chosen that would almost certainly change family planning by prospective parents or affect antenatal, perinatal, or neonatal care

Genome Coverage

close to 2M nucleotides corresponding to 7717 segments of 437 disease genes. Targeted were exons, introns, splice junctions, regulatory regions and UTR

Samples: 104 unrelated individuals, 76 were known to be carrier or affected

Target capture: Agilent SureSelect hybrid capture, RainDance microdroplet PCR

NGS: Illumina GAIIx, SOLiD, Illumina HiSeq

Workflow



Statistics

Table 1. Sequencing, alignment, and coverage statistics for target enrichment and sequencing platforms.

| Sample set | Enrichment S method | Sequencing method | Multi- plexing | Read length (nt) | Quality score* | Total reads ± %CV* [†] | % uniquely aligning reads* | Total nucleotides* | Aligning depth* | % nt on target ± %CV* | Fold enrichment* | % 0× coverage* | % ≥20× [∗] coverage* | Coverage * ± %CV* | Pearson's coefficient [‡] |
|--------------------|------------------------|----------------------|-------------------|------------------------|-------------------|---------------------------------------|----------------------------------|-----------------------|--------------------|-----------------------------|---------------------|-------------------|----------------------------------|----------------------|------------------------------------|
| 1 (<i>n</i> = 12) | SureSelect | GAllx | 12 | 50 | 30 | 9,952,972.5 ± 21 | 94 | 497,648,625 | 225 | 13.7 ± 3 | 214 | 4.83 | 61 | 27 ± 21 | 0.28 |
| 2 (<i>n</i> = 12) | SureSelect | GAllx | 12 | 50 | 30 | 10,127,721 ± 16 | 95 | 506,386,025 | 234 | 23.0 ± 2 | 358 | 3.66 | 80 | 50 ± 16 | 0.19 |
| 1 + 2 (n = 24) | RainDance | GAllx | 12 | 50 | 36 | 9,412,698 ± 30 | 97 | 470,634,900 | 196 | 29.6 ± 5 | 462 | 5.46 | 86 | 52.5 ± 33 | 0.23 |
| 1 + 2 (n = 12) | RainDance | GAllx | 12 | 50 | 31 | 12,807,392 ± 17 | 96 | 640,369,600 | 277 | 22.2 ± 7 | 346 | 4.62 | 88 | 56 ± 12 | 0.27 |
| 3 (<i>n</i> = 6) | SureSelect | GAllx | 6 | 50 | 30 | 19,711,735 ± 34 | 95 | 985,586,750 | 463 | 17.4 ± 3 | 273 | 1.80 | 86 | 76 ± 30 | 0.14 |
| 3 (<i>n</i> = 6) | SureSelect | SOLID 3 | 6 | 50 | 24 | 16,506,076 ± 5 | 82 | 825,303,800 | 310 | 19.5 ± 7 | 304 | 6.08 | 79 | 58 ± 7 | 0.24 |
| 4 (<i>n</i> = 72) | SureSelect 2 | HiSeq | 8 | 149 [§] | 42 [§] | 9,273,596 ± 24 | 98 | 1,390,464,487 | 495 | 31.7 ± 4 | 494 | 2.33 | 92 | 152 ± 26 | 0.02 |
| 5 (<i>n</i> = 8) | SureSelect | HiSeq | 8 | 149 [§] | 41 [§] | 9,861,765 ± 35 | 97 | 1,493,946,141 | 517 | 28.4 ± 4 | 442 | 2.25 | 93 | 139 ± 40 | 0.06 |

*Median value. [†]Coeffic

[†]Coefficient of variation (%).

[‡]Pearson's median skewness coefficient [3(mean – median)/SD].

5D]. [§]After assembly of forward and reverse 130-bp paired reads.

Enrichment Techniques







SNPs are called if present in > 10 uniquely aligning reads (left figure) or > 4 uniquely aligning reads (right figure), with average quality score > 20.

SNP Genotype and Accuracy

Distribution of read count-based allele frequency





Detect Gross Deletion

Use HiSeq NGS method

Reduce penalty on polynucleotide variants [-1 - log(indel-length)]

Detect gross deletion by perfect alignment to mutant junction reference sequences or by local decrease in normalized coverage. **Deletion in CLN3**



Four known heterozygotes (red) and one undescribed carrier (green) are identified

Reads were normalized to total sequence generated in a batch

Decision Tree



Some Incorrect Annotations

| | 330 | 340 | 350 | 360 | 370 | 380 | 390 | 400 | 410 | 420 | 430 | 440 | 450 | 460 |
|--------------|---------------------------------------|-------------|-------------|-----------------------|--------------------------|--------------------------|---------------------------|-------------|--------------------------|-----------------|-----------|--------------|----------------------------|--|
| | CCAGACAAGTTTGT | TGTAGGATATO | CCCTTGACTA | TAATGAATA | CTTCAGTCA | TTTAATG | | | | | | | | |
| | | | | A | CTTCAGGGAT | TTGGAT | GTAATTGCT | TETTTTETC | ACTCATTT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | TGTTTTCTC | CTT |
| | | | | ATA | CTTCATGGA | TTGAAT | GTAATTGCT | TCTTTTCTC, | ACTCATITI | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | | |
| | | TOTOGOATATO | CCCTTGACT | TAATGAATA | CTTCAGGGA | TTGAAT | GTAATTOCT | ACTITIC | ACTOATITT | TCAAAACACOCAT | AAAAA | AUGAAAGAGAA | | LITCAGE |
| | CCAGACAAGTTTGT | TGTAGGATATG | CCCTTGACTA | TAATGAATA | CTTCAGGGAI | TTGAAT | GTAATTGCT | | | CARACTOCA | | | | |
| | CCAGACAAGTTTGT | TOTAGGATATO | CCCTTGACTA | TAATGAATAI | CTTCAGGGA | TTGAAT | GTAATTOCT | | | | | | | |
| | CCAGACAAGTTTGT | TGTAGGATATG | CCCTTGACTA | TAATGAATA | CTTCAGGGAT | TTGAAT | - GTAATTGCT | | | | | | | |
| | | TGTAGGATATG | CCCTTGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | GTAATTGCT | TCTTTTTCTC | ACTCATIT | TCAAAACACGCAT | AAA | | | |
| | | TGTAGGATATG | CCCTTGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | - GTAATTOCT | TCTTTTTCTC | ACTCATTT | TCAAAACACOCAT | AAA | | | |
| | | TGTAGGATATG | CCCTTGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | GTAATTGCT | TCTTTTTCTC | ACT <mark>CA</mark> TTTT | TCAAAACACGCAT | AAA | | | |
| | | TGTAGGATATG | CCCTTGACTA | TAATGAATA | C T T C AGGGA | TTGAAT | - GTAATTGCT | TCTTTTTCTC | ACT <mark>CA</mark> TTTT | TCAAAACACGCAT | AAA | | | |
| | | TGTAGGATATG | CCCTTGACTA | TAATGAATA | CTTCAGGGA | TT TGAAT | - GTAATTGCT | TCTTTTTCTC | ACT <mark>CA</mark> TTTT | TCAAAACACGCAT | AAA | | | |
| | | TGTAGGATATG | CCCTTGACTA | TAATGAATA | CTTCAGGGAT | TTGAAT | - GTAATTGCT | TETTTTETC | ACT <mark>CA</mark> TTTT | TCAAAACACGCAT | AAA | | | |
| | | TGTAGGATATG | CCCTTGACTA | TAATGAATAG | CTTCAGGGAT | TTGAAT | - GTAATTGCT | TETTTTTETC | ACTCATITT | TCAAAACACGCAT | AAA | | | |
| | | | | · · · · · · · · · · A | CTTCAGGGA | TTGAAT | - GTAATTGCT | TCTTTTTCTC/ | ACTCATITI | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | | CTT |
| | | | | | CTTCAGGGA | TTAAAT | - GTAATTOCT | | ACTOATTT | TCARACCOCCAT | AAAAATTT | AGGAAAGAGAA | | |
| | | | | | CTTCAGGGA | TTGAAT | GTAGTTOCT | TOTITIC | ACTOATITT | TCARAACACOCAT | AAAAATTT | AGGAAAGAGAA | | |
| | | TGTAGGATATG | CCCTTGACT | TAATGAATA | CTTCAGGGA | TTGAAT | GTAATTACT | TOTITIC | ACTCATIT | TCAATACACGCAT | 0.0.0 | | | |
| | | TOTAGGATATO | CCCTTGACTA | TAATGAATA | CTTCAGGGAT | TTGAAT | . GTAATTOCT | TOTTTTTCTC | ACTCATIT | TCAAAACACGAAT | AAA | | | |
| | | | | AI | CTTCAGGGA | TTGAAT | - GTAATTOCT | TCTTTTTCTC | ACTCATTT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | TUTTTTET | CTT |
| | | | | A | CTTCAGGGA | TTGAAT | GTAATTGCT | TCTTTTTCTC | ACT <mark>CA</mark> TTTT | TCAAAACACGCAT | AAAAA | AGGAAAGAGAA | гт <mark>оттттс</mark> тс | <mark>стт</mark> |
| | | | | AI | CTTCAGGGA1 | TT <mark>GAAT</mark> ··· | - GTAATTGET | TCTTTTTCTC | ACT <mark>CA</mark> TTTT | T CAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | ГТ <mark>ӨТТТТ</mark> СТСІ | <mark>стт</mark> |
| | | | | · · · · · · · · A | C <mark>TT</mark> CAGGGA | TTGAAT | - GTAATTGCT | TCTTTTTCTC | ACT <mark>CA</mark> TTTT | T CAAAACACGCA T | AAAAA | AGGAAAGAGAA | TT <mark>GTTTTC</mark> TCI | <mark>с т т</mark> |
| | | | | A | CTTCAGGGA | TTGAAT | - GTAATTGCT | TCTTTTTCTC | ACT <mark>CA</mark> TTTT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | TTGTTTT <mark>CTC</mark> | C T T |
| | | | | A | CTTCAGGGA | TTGAAT | - GTAATTGCT | TCTTTTTCTC | ACTCATTT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | , T <mark>GTTTTC</mark> TC | CTT |
| | | | | Al | CTTCAGGGAT | TTGAAT | GTAATTGCT | TETTTTETC | ACTCATITT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | | CTT |
| | | | | A | CTTCAGGGA | TIGAAT ···· | GTAATTOCT | | ACTCATTTT | TCAAAACACGCAT | AAAAA | AGGAAAGAGAA | | CIT |
| | •••••• | IG AGGATATO | ACCCTTGACTA | AAIGAAIAI | CTTCAGGGA | TTGAAT | - GTAATTGCT | TOTITIO | ACTCATIT | TCARAACACOCAT | AAAAATTT | | TATTTCTC | |
| | | | TAACTA | TAATGAATA | CTTCAGGGA | TTOAAT | ATAATTACT | TOTTTTCC | ACTOANTTT | TCAAAACACOCAT | AAAAATTT | AGGAAAGAGAGA | | • |
| | | | TGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | GTAATTOCT | TETTTTETC | ACTCANTT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGA. | | |
| | | TGTAGGATATG | CCCTTGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | GTAATTOCT | TCTTTTTCTC | ACTCATITT | TCAAAACACGCAT | AA | | | |
| | CCAGACAAGTTTGT | TOTAGGATATO | CCCTTGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | - GTAATTOCT | TCTTTTTCTC | ACTC | | | | | |
| | · · · · · · · · · · · · · · · · · · . | TOTAGGATATO | OCCCTTGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | - GTAATTOCT | TETTTTETC | ACT <mark>CA</mark> TITI | TCAAAACACOCAT | AA | | | |
| | | | | · · · · · · · · A | CTTCAGGGA | TTGAAT | - GTAATTGCT | TCTTTTTCTC | ACT <mark>CA</mark> TTTT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | AGTTTTCTC | <mark>С Т Т</mark> |
| | | | | · · · · · · · · · A(| C T T C AGGGA | TTGAAT | - GTAATTGCT | TCTTTTTCTC | ACT <mark>CA</mark> TTTT | TCAAAACACGCAT | AAAAA TTT | AGGAAAGAGATI | TTGTTTT <mark>CT</mark> C | C T T |
| | | | | · · · · · · · · · A | CTTCAGGGAT | TTGAAT | - GTAATTGCT | TCTTTTTCTC | ACTCATITT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | TGTTTTCTC | G T T |
| | | | | A | CTTCAGGGAI | TTGAAT | GTAATTGCT | TETTTTETE | ACTCATITT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGAA | GTTTTTC | CT |
| | | | | | CTTCAGGGA | TTOAAT | - GTAATTGCT | TOTITIC | ACTEATIT | TCARACACOCAT | AAAAATTT | AGGGAAGAGAA | | |
| | | | | | CTTCAGGGA | TIGAAT | GTAATTGL | TOTTTTCTC | ACTCATIT | TCARACALGUAT | AAAAATTT | AGGAAAGAGAAA | | |
| | CCAGACAAGTTTAT | TATAGGATATA | CNCTTGACT | TAATGAATAG | CTTCAGGGA | TTGGGT | ATAATTACT | | ACTO ATT T | CARACTORCA | | | | |
| | | | ···· TGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | GTAATTOCT | TETTTTCTC | ACTCATIT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGA - | | |
| | | | TGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | GTAATTGCT | TETTTTETE | ACTCATTT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGA - | | |
| VEN 1011 121 | | | TGACTA | TAATGAATA | CTTCAGGGA | TTGAAT | - GTAATTGCT | TCTTTTTCTC | ACTCATTT | TCAAAACACGCAT | AAAAATTT | AGGAAAGAGA | | |
| C 22 | Q | | | - AATGAATA | CTTCAGGGA | TTGAAT | - GTAATTGCT | TCTTT | | | | | | |
| C_25 | CCAGACAAGTTTGT | TGTAGGATATG | CCCTTGACTA | TAATGAATA | CTTCAGGGA | TTGAATGTA | AGTAATTGCT | TCTTTTTCTC | ACTCATIT | TCAAAACACGCAT | AAAAA | AGGAAAGAGAA | TGTTTTCTC | CTTCCAG |
| | | | | | PERSONAL PROPERTY OF THE | | All Michael Rich Like and | | | | | | | |
| | | | | | | | | 100 | and the second | 201 <u>201</u> | | | | |
| | | | | | | | | | | | 1 | | | |
| | * | | | | | | | | | | | | | 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 |

Sample: an affected male with X-linked recessive Lesch-Nyhan syndrome Before: characterized as deletion of HPRT1 exon 8 by cDNA sequencing Actual: splicing mutation of IVS intron 8.

Some Incorrect Annotatios



Sample: an affected male with X-linked recessive Pelizaeus-Merzbacher disease

Before: substitution mutation in PLP1 exon 5 c.67C>T, P215S

Actual: PLP1 gene duplication

Some Incorrect Annotatios

Read: 18811751 SNPSTER4 0001:4:120:1673:504#ACTTGA/1 Length: 50 Identities = 48/50(96) Strand = Plus/Plus Alignment = Unique Query: 1 attaaatgtgtgcatacceteeaataatttggetgggaattetgageaag 50 Sbjct: 178596876 attaaatgtgtgcataccctccaataatttggctggcaattccgagcaag 178596925 Read: 11118413 SNPSTER4 0001:7:23:829:624#ACTTGA/1 Length: 50 Identities = 48/50(96) Strand = Plus/Minus Alignment = Unique Query: 50 taaatgtgtgcataccctccaataatttggctgggaattctgagcaagcc Sbjct: 178596878 taaatgtgtgcataccctccaataatttggctggcaattccgagcaagcc 178596927 Read: 11070753 SNPSTER4 0001:7:19:991:1922#ACTTGA/1 Length: 50 Identities = 48/50(96) Strand = Plus/Plus Alignment = Unique Query: 1 taaatgtgtgcataccctccaataatttggctgggaattctgagcaagcc 50 Sbjct: 178596878 taaatgtgtgcataccctccaataatttggctggcaattccgagcaagcc 178596927 Read: 3850380 SNPSTER5:1:3:530:785#TGACCA/1 Length: 50 Identities = 48/50(96) Strand = Plus/Plus Alignment = Unique Query: 1 aaatgtgtgcataccctcca<mark>a</mark>taatttggctgggaattctgagcaa<mark>gc</mark>ca 50 Sbjct: 178596879 aaatgtgtgcataccctccaataatttggctggcaattccgagcaagcca 178596928 Read: 22935831 SNPSTER1 0594:2:17:9570:11638#TGACCA/1 Length: 50 Identities = 48/50(96) Strand = Plus/Minus Alignment = Unique Query: 50 aaatgtgtgcataccetecaataatttggetgggaattetgageaageea Sbjet: 178596879 aaatgtgtgcataccctccaataatttggctggcaattccgagcaagcca 178596928

Sample: an affected female with aspartylgucosaminuria

Before: characterized as compound heterozygotes

Actual: homozygous for two adjacent substitutions

Some Incorrect Annotatios



Sample: affected with Cockayne syndrome B

Before: deletion of ERCC6 exon 9

Actual: no gross deletion was observed

Carrier Burden

336 variants were retained as likely disease mutations in 104 samples;



A variant was retained reported in HGMD and literature, had been shown to result in LOF, was the only variant in affected individuals and absent in control, and was predicted to result in premature stop codon or loss substantial protein portion

Average: 2.8 / genome

Ward hierarchical clustering of 227 DM in 104 samples

Resulting pattern is random, suggesting that targeted population testing is likely to be ineffective



Conclusions

- Described a screening test (target capture + NGS) for carriers of 448 severe childhood recessive diseases
- Found a list of incorrect literatureannotated disease mutations
- Estimated the average carrier burden (2.8) of disease mutations causing severe childhood recessive diseases.

Future Challenges

- Refinement of list of diseases
- Automation, software implementation
- Validation in realistic testing situations featuring investigator blinding
- Ethic concerns